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Runx2 transcribes Runx2-II and Runx2-I isoforms with distinct N-termini. Deletion of both isoforms results in complete arrest of bone
development, whereas selective loss of Runx2-II is sufficient to form a grossly intact skeleton with impaired endochondral bone
development. To elucidate the role of Runx2-II in osteoblast function in adult mice, we examined heterozygous Runx2-II (Runx2-II+/) and
homozygous Runx2-II (Runx2-II/)-deficient mice, which, respectively, lack one or both copies of Runx2-II but intact Runx2-I expression.
Compared to wild-type mice, 6-week-old Runx2-II+/ had reduced trabecular bone volume (BV/TV%), cortical thickness (Ct.Th), and bone
mineral density (BMD), decreased osteoblastic and osteoclastic markers, lower bone formation rates, impaired osteoblast maturation of
BMSCs in vitro, and significant reductions in mechanical properties. Homozygous Runx2-II/ mice had a more severe reduction in BMD,
BV/TV%, and Ct.Th, and greater suppression of osteoblastic and osteoclastic markers than Runx2-II+/ mice. Non-selective Runx2+/ mice,
which have an equivalent reduction in Runx2 expression due to the lack one copy of Runx2-I and II, however, had an intermediate reduction
in BMD. Thus, selective Runx2-II mutation causes diminished osteoblastic function in an adult mouse leading to low-turnover osteopenia
and suggest that Runx2-I and II have distinct functions imparted by their different N-termini.
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Runx2 is a master gene regulating bone development.
The Runx2 gene produces two major transcripts driven by
alternative promoters designated P1 and P2, respectively
(Fig. 1). Runx2 Type I (Runx2-I) is derived from the P2
proximal promoter and begins with the sequence MRIPV
encoded by Exon 2. Runx2 Type II (Runx2-II, formerly
called Osf2) is controlled by the P1 distal promoter and
begins with MASNS encoded by exon 1 (Ducy et al., 1997;0012-1606/$ - see front matter D 2005 Published by Elsevier Inc.
doi:10.1016/j.ydbio.2005.04.028
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E-mail address: dquarles@kumc.edu (L.D. Quarles).Harada et al., 1999). Thus, there are 4 alleles that generate
two distinct gene products, Runx2-I and Runx2-II, which
differ only by the amino acids at their N-terminal regions
(Fig. 1) (Banerjee et al., 2001; Xiao et al., 1999). Ho-
mozygous Runx2 null mice (derived from inactivating
mutations affecting all four alleles) results in arrested bone
formation and the complete lack of all mineralized skeletal
elements due to the absence of osteoblastic differentiation
(Komori et al., 1997; Otto et al., 1997). Haploinsufficiency
of both Runx2-I and Runx2-II gene products causes
cleidocranial dysplasia (CCD), an autosomal dominant
disorder characterized by defective bone formation (Choi
et al., 2001; Mundlos et al., 1997; Nakashima and de283 (2005) 345 – 356
Fig. 1. Diagrams of Runx2 alleles and gene products in non-selective Runx2 and selective Runx2-II-deficient mice. (A) Heterozygous Runx2+/ mice have one
copy of wild-type Runx2 alleles predicted to generate 1/2 of the normal Runx2-I and Runx2-II gene products. (B) Homozygous Runx2/ mice have neither
wild-type Runx2 alleles nor Runx2-I and Runx2-II gene products. (C) Heterozygous Runx2-II+/ mice have one wild-type Runx2 allele and one Runx2-II
mutant allele. These mice should express normal amounts of Runx2-I and 1/2 the amount of Runx2-II gene products. (D) Homozygous Runx2-II/ mice have
two mutant Runx2-II alleles predicted to produce normal amounts of Runx2-I but no Runx2-II gene products. P1 or P2 designates the promoter regions for
Runx2-II or Runx2-I, respectively.
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also have been described that result in mild CCD or dental
phenotype characterized by delayed eruption of permanent
teeth (Zhou et al., 1999).
The separate functions of Runx2-I and -II in vivo are not
clearly understood. Several observations, however, support
the possibility that Runx2-I and -II have distinct functions.
These include different expression patterns (Choi et al.,
2002; Park et al., 2001), response to hormones and growth
factors (Banerjee et al., 2001), and evidence for differential
transactivation potential of the N-termini in cell culture
models (Harada et al., 1999; Xiao et al., 1999). Runx2-II,
previously called Osf2, is widely believed to be the
‘‘osteoblast-specific’’ isoform (Ducy et al., 1997). We
previously developed a selective Runx2-II knockout mouse
model to characterize its role in skeletogenesis. These
studies, which were limited to newborn mice, found that
selective deletion of the Runx2-II isoform resulted in a less
severe skeletal phenotype compared to deletion of both
isoforms, indicating that Runx2-I was sufficient for gross
skeletal development. Whereas combined Runx2-I and -II
null mice completely lacked a mineralized skeleton, the
selective Runx2-II null mice formed an intact mineralized
skeleton, but displayed a greater impairment of endochon-
dral bone development compared to intramembranous and
cortical bone formation (Xiao et al., 2004). Mice with
selective deletion of Runx2-II also had improved survival
compared to the deletion of both isoforms, thereby allowing
assessment of the post-natal effects of selective Runx2-II
deficiency.
In the present study, we characterized the impact of
selective Runx2-II deficiency on osteoblast function in adult
bone. We examined bone mineral density (BMD), micro-
computed tomography (CT), and 3-point bending biome-
chanical testing of femurs as well-assessed biochemicalmarkers, gene-expression profiles, bone histology, and bone
marrow stromal cell (BMSC) cultures in wild-type (Runx2-
II+/+) and Runx2-II heterozygous (Runx2-II+/) mice for up
to 24 weeks of age.Materials and methods
Animals
Selective Runx2-II mutant mice (129SVJ and C57BL/6
mixed background), lacking the type II isoform, but with
intact Type I isoform (Figs. 1C, D), were produced as
previously described (Xiao et al., 2004). Heterozygous,
homozygous Runx2-II mutant mice and wild-type litter-
mates were generated by mating F2 heterozygous Runx2-II
mutant mice. Less than 10% of Runx2-II/ mice survived
past 6 weeks, from which six were selected for evaluation.
We used 40 wild-type and 100 Runx2-II+/ mice in these
studies. In addition, we examined the bone mineral density
in heterozygote non-selective Runx2 mutant mice, lacking
one copy of both Type I and Type II isoform (Figs. 1A, B).
These mice were obtained from Dr. Gerard Karsenty (Otto
et al., 1997). Heterozygous non-selective Runx2 mutant
mice (Runx2+/) and wild-type littermates were generated
by mating heterozygous Runx2 mutant mice.
Bone densitometry, skeletal radiography, and
nondecalcified bone histological preparations
Bone mineral density (BMD) of whole femurs and
lumbar spines were assessed at 6, 12, and 24 weeks of
age using a PIXImusi bone densitometer (Lunar Corp.,
Madison, Wisconsin, USA) as previously described (Tu et
al., 2003). Six-week-old mice were radiographed using a
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tons of mice were prelabeled with tetracycline hydrochlo-
ride (Sigma T-7660, 30 Ag/g body weight) and calcein
(Sigma C-0875, 30 Ag/g body weight) by intraperitoneal
injection at days 1 and 5 in 6- and 24-week-olds prior to
collection of tibias. Tibias were removed from 6- and 24-
week-old mice, fixed in 70% ethanol, prestained in
Villanueva stain and processed for methyl methacrylate
embedding. Five-Am sections were stained with Goldner’s
stain and analyzed under transmitted light, and 10-Am
Villanueva prestained sections were evaluated under fluo-
rescent light as reported previously by our laboratory (Tu et
al., 2003).
Micro-CT analysis
The distal femoral metaphyses were scanned using a ACT
40 (Scanco Medical AG, Bassersdorf, Switzerland); 167
slices of the metaphyses under the growth plate, constituting
1.0 mm in length, were selected. The three-dimensional
(3D) images were generated using the following values for a
gauss filter (sigma 0.8, support 1) and a threshold of 275. A
3D image analysis was performed to determine bone
volume (BV/TV), trabecular number (Tb.N), trabecular
thickness (Tb.Th), and trabecular separation (Tb.Sp). Cor-
tical bone was measured on the mid-shaft region of cortical
bone in 50 slices of the diaphysis, constituting 0.3 mm in
length. The mean cortical thickness (Ct.Th) was determined
at 8 different points on the cortical slice.
Serum biochemical measurements
Serum osteocalcin levels were measured using a mouse
osteocalcin EIA kit (Biomedical Technologies Inc., Sto-
ughton, MA, USA). Serum Calcium (Ca) was measured by
the colorimetric cresolphthalein binding method, and
phosphorus (P) was measured by the phosphomolybdate–
ascorbic acid method (Tu et al., 2003). Serum osteoprote-
gerin (OPG) and RANK ligand (RANK-L) were measured
using mouse ELISA kits (Quantikine\, R&D systems), and
serum TRAP was assayed with the ELISA-based SBA
Sciences mouseTRAPi assay (Suomen Bioanalytiikka
Oy).
Alkaline phosphatase activity and mineralization assays in
bone marrow stromal cell cultures
Bone marrow stromal cells from 6- or 24-week-old mice
were prepared as previously described (Xiao et al., 2001).
The adherent cells (representing bone mesenchymal stem
cells, BMSCs) were grown for periods of up to 12 days in
the differentiation medium (a-MEM containing 10% v/v
FBS supplemented with 5 mM h-glycerophosphate and 25
Ag/ml of ascorbic acid) for inducing osteoblastic differen-
tiation of BMSCs. Alkaline phosphatase (ALP) activity and
Alizarin Red-S histochemical staining for mineralizationwere performed as previously described (Xiao et al., 1998).
For quantification of mineralization, Alizarin Red-S was
extracted with 10% cetylpyridinium chloride and assessed at
562 nm. Total DNA content was measured with a
PicoGreen\ dsDNA quantitation reagent and kit (Molecular
Probes, Eugene, OR).
Real-time RT-PCR
For quantitative real-time RT-PCR, 2.0 Ag total RNA
isolated from long bone of 6- and 24-week-old mice was
reverse transcribed as described (Xiao et al., 2003). PCR
reactions contained 100 ng template (cDNA or RNA), 300
nM each forward and reverse primer and 1X iQi SYBR\
Green Supermix (Bio-Rad, Hercules, CA) in 50 Al.
Samples were amplified for 40 cycles in an iCycler iQi
Real-Time PCR Detection System with an initial melt at
95-C for 10 min followed by 40 cycles of 95-C for 15 s
and 60-C for 1 min. PCR product accumulation was
monitored at multiple points during each cycle by
measuring the increase in fluorescence caused by the
binding of SybrGreen I to dsDNA. The threshold cycle
(Ct) of tested-gene product from the indicated genotype
was normalized to the Ct for cyclophilin A.
Biomechanical testing
Femurs were dissected and cleaned from muscle and soft
tissue attachments, and then frozen at 20-C until testing.
On the day of testing, the bones were thawed and rehydrated
with PBS for 3 h. Bending tests were performed using a
three-point fixture on an electromechanical testing system
(ELF 3200, EnduraTEC, Inc., and Minnetonka, MN). The
bones were flexed in the anterior–posterior plane by
displacing the loading point fixture at 5 mm/min until
failure (Silva and Ulrich, 2000). Bending force–deflection
curves were constructed and analyzed for stiffness (S) and
maximum force to failure (Fmax). The flexural rigidity (EI)
was calculated from the classical equations of beam theory
for a simply-supported beam with a central concentrated
load.
Statistical analysis
We evaluated differences among the three groups (for
instance, wild-type, heterozygous and homozygous Runx2-
II-deficient mice) by one-way analysis of variance when
there was no potential for a time effect, i.e., when all three of
the groups were measured at one time point. If the global
test was significant, pairwise comparisons were performed
using Tukey’s HSD method. Variables for which we
measured in the two groups (for instance, wild-type,
heterozygous Runx2-II or Runx2-deficient mice) over time
were compared using a two-way analysis of variance with
interaction. We found no significant interactions between
group and time for any analysis. If global main effects were
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comparisons using Tukey’s HSD method. All values are
expressed as means T SEM. All computations were
performed using the Statgraphic statistical graphics system
(STSC Inc.) or SAS 9.1.Results
Gross appearance and survival rate
The survival of hetereozygous Runx2-II+/ mice was not
different from wild-type littermates and they had no gross
skeletal abnormalities by X-ray analysis, whereas homozy-
gous Runx2-II/ mice had marked growth retardation and
dwarfism (data not shown), as previously reported in
newborn mice (Xiao et al., 2004).
Bone mineral density
Wild-type (Runx2-II+/+) mice exhibited an age-associated
increase in femoral (0.061 T 0.001, 0.077 T 0.001, 0.086 T
0.001 g/cm2, Fig. 2A) and lumbar spine (0.061 T 0.001,
0.073 T 0.001, 0.075 T 0.001 g/cm2, Fig. 2B) BMD at 6, 12,
and 24 weeks, respectively. Runx2-II+/ mice, which are
deficient in only one copy of Runx2-II (Fig. 1C), also
displayed an age-dependent increase in BMD, but demon-
strated a significant reduction in both femoral and lumbar
spine BMD compared to wild-type mice at all time pointsFig. 2. Effects of genotype and age on bone mineral density (BMD). (A, B) BMD
femur and spine in non-selective Runx2-deficient mice. BMD analysis of the femo
6-, 12-, and 24-week-old in Runx2-II+/+, selective Runx2-II+/, Runx2-II/, an
femoral and lumbar spine BMD were greater in 6-week-old Runx2-II null mice co
mice. Wild-type mice from non-selective Runx2-deficient strain have a lower BMD
the fact that that they are derived from a different genetic background. Data re
#difference from heterozygous Runx2-II+/ mice at P values specified below the b
and 24 weeks were also significantly different (as indicated by brackets above th(Figs. 2A, B). Bone loss in Runx2-II+/ mice was greater in
lumbar spine, which is predominately trabecular bone, than
the femur, which is a mixture of trabecular and cortical
bone. Six-week-old Runx2-II null mice, which lack both
copies of Runx2-II but retain both copies of Runx2-I (Fig.
1D), had a more severe reduction in both femoral (39%) and
lumbar spine (34%) BMD compared to heterozygous
Runx2+/ mice, consistent with a dose-dependent effect of
Runx2-II in regulating bone mineral density.
To further define the role of Runx2-I and -II isoforms and
gene dosage, we determine the effects of loss of both Runx2-
I and -II isoforms (Fig. 1A) on BMD using the originally
described heterozygous Runx2+/mice created by disruption
of the common Runx binding domain (Otto et al., 1997).
Compared with their wild-type littermates, heterozygous
Runx2 mutant mice, which lack one copy of Runx2-I and -II
(Fig. 1A), exhibited a 13% reduction in femoral BMD
(0.0455 T 0.001 vs. 0.0524 T 0.001 g/cm2, Fig. 2C) and a
14% reduction in lumbar spine BMD (0.04210 T 0.001 vs.
0.0491 T 0.001 g/cm2, Fig. 2D). The loss of one copy of both
Runx2-I and -II in the femur resulted in a phenotype
intermediate to that of Runx2-II/ and Runx2-II+/ mice
(vide supra), indicating that a 50% reduction in Runx2 from
the loss of both copies of the Type II isoform leads to a
greater degree of osteopenia than a equivalent reduction
caused by loss of one copy each of the Type I and II isoforms
(Figs. 2A and C). Comparison of the heterozygous selective
Runx2-deficient and the original Runx2-deficient mice also
revealed site-specific differences in bone loss. In this regard,of femur and spine in selective Runx2-II-deficient mice. (C, D) BMD of
ral and lumbar spine was assessed by the PIXImusTM mouse densitometer at
d non-selective Runx2+/+, Runx2+/, Runx2/ mice. Reductions in both
mpared to heterozygous selective Runx2-II+/ and non-selective Runx2+/
compared to wild-type mice used in the proceeding analysis, likely due to
present the mean T SEM. *Difference from wild-type Runx2-II+/+ mice;
ar graft at each time point. The time-dependent increments in BMD at 6, 12,
e bar graphs).
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whether mice lost one copy of Runx2-II (Runx2-II+/) or one
copy each of Runx2-I and Runx2-II (Figs. 2B and D).
lCT evaluation
ACT analysis was performed to further determine the
relative contribution of cortical and trabecular bone to these
changes in femoral BMD. Wild-type (Runx2-II+/+) mice
displayed an age-dependent reduction in trabecular bone
volume and an age-dependent increase in cortical bone
thickness of the femur (Table 1). In 6-week-old Runx2-II-
deficient mice, we observed a gene-dose-dependent reduc-
tion in BV/TV%, Tb.N, Tb.Th, and Ct.Th (Fig. 3 and Table
1) as evidenced by the more severe reductions in these
parameters in 6-week-old homozygous Runx2-II mice
compared to Runx2-II+/ mice (Table 1). At 24 weeks of
age, Runx2-II+/ mice had persistent reductions in trabec-Table 1
Micro-CT analysis of femurs in wild-type and mutant mice
Genotype Runx2-II+/+ Runx2-II+/ Runx2-II/
BV/TV (%)
6 weeks 21.2 T 1.4 14.8 T 1.4a
( P = 0.0039)
7.1 T 1.4a,b
( P = 0.0027)
24 weeks 14.5 T 1.2c 9.6 T 1.3a,c
( P = 0.0062)
–
( P < 0.0001) ( P < 0.0001)
Tb.N (mm1)
6 weeks 6.44 T 0.20 5.43 T 0.21a
( P = 0.0026)
3.91 T 0.26a,b
( P = 0.0002)
24 weeks 4.65 T 0.20c 4.04 T 0.21a,c
( P = 0.0257)
–
( P = 0.0014) ( P = 0.0133)
Tb.Th (mm)
6 weeks 0.045 T 0.001 0.041 T 0.001a
( P = 0.0333)
0.035 T 0.001a,b
( P = 0.0343)
24 weeks 0.046 T 0.002 0.041 T 0.002a
( P = 0.0050)
–
( P = 0.6158) ( P = 0.9855)
Tb.Sp (mm)
6 weeks 0.149 T 0.010 0.184 T 0.011a
( P = 0.0280)
0.266 T 0.013a,b
( P < 0.0001)
24 weeks 0.217 T 0.011c 0.254 T 0.011a,c
( P = 0.0090)
–
( P < 0.0001) ( P < 0.0001)
Ct.Th (mm)
6 weeks 0.18 T 0.01 0.16 T 0.01a
( P = 0.0475)
0.13 T 0.01a,b
( P < 0.0001)
24 weeks 0.241 T 0.005c 0.236 T 0.005c
( P = 0.4331)
–
( P < 0.0001) ( P < 0.0001)
Data are mean T SEM from 6 individual mice.
a Significant difference from wild-type Runx2-II+/+ mice.
b Significant difference from heterozygous Runx2-II+/ mice.
c Difference between 6 and 24 weeks at the indicated P value using
statistical analysis described in Materials and methods.ular bone volume (30% vs. 34% in 6-week-old and 24-
week-old Runx2-II+/ mice, respectively), but during this
time, cortical bone thickness increased in both wild-type and
Runx2-II+/ mice and attained levels that were no longer
significantly different (Fig. 3 and Table 1). Thus, the loss of
bone mass by BMD in 24-week-old Runx2-II+/ mice (Fig.
2) was predominantly due to loss of trabecular bone volume
in the femoral metaphysis. These findings are consistent
with our previous report of the selective preservation of
cortical bone formation in Runx2-II-deficient mice (Xiao et
al., 2004).
Histology
To understand the cellular basis for these structural
changes and to identify potential mechanisms responsible
for the reduced bone mass in Runx2-II-deficient mice, we
examined histological sections of the epiphyseal bone,
growth plate, and metaphyseal bone of tibia of 6-week-old
wild-type, heterozygous, and null mice (Figs. 4A, B).
Heterozygous Runx2-II+/ mice displayed reduced trabecu-
lar bone volume and normal appearing growth plate as well
as normal bone shape and length, consistent with the X-ray,
BMD, and ACT structural analysis. Mineral apposition rates
in trabecular bone of the metaphyseal region as assessed by
dual fluorescent labeling were reduced; in contrast, miner-
alization on the periosteal and endosteal surfaces of cortical
bone was preserved in Runx2-II+/-deficient mice (Figs. 4C,
D), suggesting that Runx2-II plays a more important
function in trabecular bone compared to cortical bone. There
were no demonstrable differences in osteoblastic and
osteoclastic surfaces between wild-type and Runx2-II-
deficient mice (data not shown). Homozygous Runx2-II/
mice show a more marked reduction of trabecular bone
volume, a widened growth plate consisting of increased zone
of hypertrophic chondrocytes, and severe impairment of
bone formation, as evidenced by no double labels in
trabecular bone (Fig. 4C); however, osteoblast surfaces and
mineral apposition rates in the periosteal and endosteal bone
were preserved in Runx2-II null mice (Fig. 4D).
Biochemical bone markers and gene expression profiles
Wild-type Runx2-II+/+ mice had reduced osteoblastic and
osteoclastic markers as a function of age, consistent with an
age-dependent decrease in bone formation and resorption
(Table 2). Selective Runx2-II deficiency resulted in a further
reduction in osteoblast and osteoclast markers that was
dependent upon gene dosage. In 6-week-old heterozygous
Runx2-II+/ mice, RANK-L and TRAP were reduced com-
pared to age-matched wild-type mice, whereas reductions in
Osteocalcin were not observed until 24 weeks of age (Table
2). In 6-week-old Runx2-II/ mice, Osteocalcin (107 T 56
vs. 451 T 51 ng/ml), TRAP (2.6 T 0.49 vs. 4.5 T 0.35 U/l),
and RANK-L (28.3 T 7.2 vs. 97.6 T 5.1 pg/ml) were reduced
compared with age-matched wild-type mice (Table 2). In
Fig. 3. 3D images of femurs in 6- and 24-week wild-type and mutant mice. 3D images of metaphyseal bone (upper panel) and cortical bone (lower panel)
generated from ACT analysis. There was an age-dependent reduction in trabecular bone volume and an increase in cortical thickness in wild-type mice. The
trabecular bone volume and cortical thickness was reduced in Runx2-II+/ and Runx2-II/ mice proportionate to the reduction in gene dosage. Runx2-II+/
mice displayed an age-dependent decrease in trabecular bone and increase in cortical bone similar to wild-type mice.
Fig. 4. Nondecalcified histological sections of tibia bone in 6-week-old Runx2-II wild-type and mutant mice. (A, B) Goldner-stained sections of the epiphyseal
bone (200 magnification) and growth plate and metaphyseal bone (100 magnification) of 6-week-old Runx2-II+/+, Runx2-II+/, and Runx2-II/ mice.
Mineralized trabecular bone (Tb) is blue and unmineralized osteoid is reddish brown in color. (C, D) Villanueva-stained sections of trabecular (200
magnification) and cortical bone (400 magnification) viewed under fluorescent light in 6-week-old Runx2-II+/+, Runx2-II+/, and Runx2-II/ mice
prelabeled with tetracycline followed by calcein (double label). Heterozygous Runx2-II+/ mice have reduced trabecular bone volume, normal appearing
growth plate, and reduced bone formation rates. Homozygous Runx2-II/ mice show a marked reduction of trabecular bone volume, a widened growth plate
consisting of increased zone of hypertrophic chondrocytes, and severe impairment of bone formation as evidenced by a diffuse single label or unlabeled
trabecular bone surfaces. In contrast, mineral apposition rates on the periosteal surfaces of cortical bone were preserved in both heterozygous Runx2-II+/ and
homozygous Runx2-II/ mice. Tb.B., trabecular bone, Ct.B., cortical bone, B.M., bone marrow, G.P., growth plate, H.Z., hypertrophic zone, D.L., double
label, S.L., single label.
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Table 2
Biochemistry analysis of serum in wild-type and mutant mice
Genotype Runx2-II+/+ Runx2-II+/ Runx2-II/
Ca (mg/dl)
6 weeks 8.9 T 0.16 8.8 T 0.17
( P = 0.5921)
9.3 T 0.37
( P = 0.1856)
24 weeks 9.9 T 0.27a 9.6 T 0.29a
( P = 0.3247)
–
( P = 0.0028) ( P = 0.0194)
P (mg/dl)
6 weeks 10.5 T 0.42 10.2 T 0.44
( P = 0.6328)
11.6 T 0.95
( P = 0.1812)
24 weeks 9.5 T 0.27a 9.0 T 0.26
( P = 0.3727)
–
( P = 0.0028) ( P = 0.1326)
Osteocalcin (gg/ml)
6 weeks 451 T 51 492 T 49
( P = 0.2196)
107 T 56b,c
( P = 0.0022)
24 weeks 114 T 10a 56 T 9a,b
( P = 0.0342)
–
( P < 0.0001) ( P < 0.0001)
OPG (gg/ml)
6 weeks 2.9 T 0.18 2.5 T 0.18
( P = 0.0793)
2.7 T 0.25
( P = 0.4016)
24 weeks 2.4 T 0.23 2.3 T 0.24
( P = 0.6936)
–
( P = 0.0636) ( P = 0.4248)
RANK-L (pg/ml)
6 weeks 97.6 T 5.1 66.4 T 5.1b
( P = 0.0003)
28.3 T 7.2b,c
( P = 0.0003)
24 weeks 90.4 T 4.5 59.9 T 4.5b
( P < 0.0001)
–
( P = 0.3021) ( P = 0.3462)
TRAP (U/L)
6 weeks 4.5 T 0.35 3.0 T 0.35b
( P = 0.0078)
2.6 T 0.49b
( P = 0.5163)
24 weeks 1.9 T 0.18a 0.99 T 0.17a,b
( P = 0.0160)
–
( P < 0.0001) ( P < 0.0001)
Data are mean T SEM. from 6 to 10 individual mice. Osteocalcin, OPG, and
RANK-L are produced by osteoblasts, and TRAP is produced by
osteoclasts.
a Difference between 6 and 24 weeks at the indicated P value using
statistical analysis described in Materials and methods.
b Significant difference from wild-type Runx2-II+/+ mice.
c Significant difference from heterozygous Runx2-II+/ mice at P < 0.05
by one-way ANOVA.
Table 3
Gene-expression profiles in 6-week old mutant mice
Gene Accession no. Runx2-II+/ Runx2-II/ P value
Transcriptional factors
Runx2-II NM_009820 0.43 T 0.07a 0a,b <0.0001
Runx2-I D14636 1.05 T 0.09 0.92 T 0.13 0.716
Runx2 NM_009820 0.75 T 0.06a 0.50 T 0.09a,b <0.0001
Runx1 NM_009821 0.94 T 0.12 0.88 T 0.08 0.219
Runx3 NM_019732 0.80 T 0.10 0.91 T 0.14 0.332
Cbfh NM_022309 0.88 T 0.09 1.01 T 0.13 0.606
Msx2 NM_013601 1.27 T 0.13 0.85 T 0.19 0.135
Sox9 NM_011448 1.12 T 0.11 1.08 T 0.16 0.703
PPARg NM_011146 1.06 T 0.13 1.13 T 0.19 0.844
Dlx5 NM_010056 1.08 T 0.10 0.89 T 0.15 0.574
Osterix AF184902 0.97 T 0.09 0.40 T 0.13a,b <0.0001





NM_007431 0.90 T 0.08 0.51 T 0.11a,b 0.003
Osteocalcin NM_007541 0.76 T 0.08a 0.27 T 0.12a,b <0.0001
Osteopontin AF515708 0.74 T 0.07a 0.19 T 0.10a,b <0.0001
MEPE NM_053172 1.02 T 0.07 0.26 T 0.11a,b <0.0001
Collagen I NM_007742 0.90 T 0.09 0.45 T 0.12a,b 0.003
DMP1 MMU242625 0.80 T 0.09 0.51 T 0.13a 0.009
Osteoprotegerin MMU94331 0.95 T 0.09 0.78 T 0.13 0.357
RANK ligand NM_011613 0.67 T 0.09a 0.32 T 0.13a,b <0.0001
MMP13 NM_008607 0.70 T 0.08a 0.36 T 0.12a,b <0.0001
VEGFA NM_009505 0.78 T 0.10 0.60 T 0.15a 0.041
Osteoclast
TRAP NM_007388 0.73 T 0.08a 0.40 T 0.11a,b <0.0001
MMP9 NM_013599 0.90 T 0.07 0.53 T 0.11a,b 0.004
Chondrocyte
Collagen II NM_031163 1.25 T 0.14 0.91 T 0.20 0.264
Collagen X NM_009925 1.09 T 0.13 0.37 T 0.19a,b 0.010
Adipocyte
aP2 NM_024406 0.96 T 0.12 1.28 T 0.17 0.292
Lipoprotein
lipase
NM_008509 1.01 T 0.11 1.16 T 0.16 0.659
PPARg, peroxisome proliferator-activated receptor g; MEPE, matrix
extracellular phosphoglycoprotein; DMP1 , dentin matrix protein 1;
VEGFA, vascular endothelial growth factor A; TRAP, tartrate-resistant acid
phosphatase; MMP, matrix metalloproteinase; aP2, adipocyte fatty acid-
binding protein 2. Data are mean T SEM from 6 to 10 6-week-old
individual mice and expressed as the fold changes relative to the
housekeeping gene cyclophilin A subsequently normalized to wild-type
mice.
a Significant difference from wild-type Runx2-II+/+.
b Significant difference from heterozygous Runx2-II+/ mice at P < 0.05
by one-way ANOVA.
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osteoclastogenesis, was reduced by approximately 25% in
heterozygous Runx2-II+/ mice and 70% in homozygous
Runx2-II/ mice compared to wild-type littermates, con-
sistent with the reduction in osteoclastic markers (Table 2).
These data suggest that the selective loss of Runx2-II results
in diminished osteoblast and osteoclast function and
consequent low-turnover osteopenia. The loss of Runx2-II
had no effect on serum calcium and phosphorus levels at
either 6 or 24 weeks (Table 2).With regards to gene expression profiles, the selective
Runx2-II+/ mice displayed approximately 50% reduction
of Runx2 Type II isoform and 25% reduction of total
Runx2, whereas the selective Runx2-II/ mice had
undetectable levels of Runx2 Type II isoform and 50%
reduction of total Runx2. As compared with wild-type
mice, we found that the expression of osteogenic
transcription factors, such as Runx1, Runx3, Msx2, Dlx5,
Sox9, and Runx2 Type I isoform, were normal in Runx2-
II+/ and Runx2-II/ mice (Table 3); however, Osterix
and Ihh were significantly lower in Runx2-II/ mice,
Z. Xiao et al. / Developmental Biology 283 (2005) 345–356352indicating loss of Runx2-II down-regulates these key genes
involved in osteoblastic differentiation (Nakashima et al.,
2002; Nakashima and de Crombrugghe, 2003).
In addition, both osteoblastic and osteoclastic cell type
markers were down-regulated in Runx2-II+/ and Runx2-
II/ mice in proportion to the reduction in Runx2-II gene
dosage (Table 3), indicating both osteoblastic and osteo-
clastic activities were impaired in Runx2-II deficient mice.
Indeed, we confirmed and extended the analysis of
osteoblast and osteoclastic function in bone by examining
gene expression profiles by real-time PCR using total RNA
isolated from long bone of 6-week-old mice. Our findings
of message expression for RANK-L, Osteocalcin, OPG, and
TRAP were concordant with the circulating amounts of
proteins for these factors. With regard to osteoblastic
markers, message levels of RANK-L, Osteoponin (OPN),
MMP13, and Osteocalcin (Osc) were significantly reduced
in heterozygous Runx2-II+/ mice, whereas OPG was
normal. The message for the osteoclastic marker TRAP
was also reduced in heterozygous Runx2-II+/ mice. In
contrast, we only observe significant decrements in hyper-
trophic chondrocyte gene makers, including Type X and
VEGFA in selective Runx2-II/ mice, consistent with the
observation that Runx2-II is predominantly expressed in
hypertrophic chondrocyte and especially involved in hyper-Fig. 5. Assessment of osteoblastic differentiation in BMSCs cultures from 6-
mineralization nodules. BMSCs from 6- and 24-week mice were cultured for 12 da
dependent decrease in mineralized nodule formation and the heterozygous BMSC
mineralization. Alizarin Red-S was extracted with 10% cetylpyridinium chloride
BMSCs had significantly lower Alizarin Red-S accumulation at day 12 of cultur
activity. The heterozygous BMSCs had significantly lower ALP activity at day
osteoblast function in Runx2-II mutant mice. Data represent the mean T SEM. *Dif
graft at each time point. The time-dependent decrements in mineralization but not A
by brackets above the bar graphs).trophic zone remodeling (Park et al., 2001). There were no
changes in adipocyte markers in Runx2-II+/ and Runx2-
II/ mice (Table 3).
BMSCs cultures
To further confirm the osteoblast function defects in
Runx2-II-deficient mice, we performed BMSC cultures
derived from age-matched Runx2-II+/+ and Runx2-II+/
mice grown in osteoblastic differentiation media for up to
12 days. There was an age-dependent decrease in mineral-
ized nodule formation but not ALP activity at 6- and 24-
week Runx2-II+/+ mice (Figs. 5A, C). Compared with age-
matched wild-type BMSC, Runx2-II+/ cultures showed
less abundant mineralized nodules and had significantly
lower Alizarin Red-S accumulation at day 12 of culture
(Figs. 5A, B). The Runx2-II+/ BMSC cultures also dis-
played significantly lower ALP activity at day 8 of culture
compared with age-matched wild type (Fig. 5C).
Mechanical testing
To explore the functional consequences of loss of
Runx2-II, we used 3-point bending tests to determine the
biomechanical properties of femurs from Runx2-II-defi-and 24-week wild-type and mutant mice. (A) Histochemical staining of
ys in differentiation media and stained with Alizarin Red-S. There is an age-
cultures showed less abundant mineralized nodules. (B) Quantification of
and quantified as described in Materials and methods. The heterozygous
e compared with age-matched wild type. (C) Alkaline phosphatase (ALP)
8 of culture compared with age-matched wild-type, indicating reduced
ference from wild-type Runx2-II+/+ mice at P values specified below the bar
LP activity at 6 and 24 weeks were also significantly different (as indicated
Table 4
Biomechanical properties of femurs in wild-type and mutant mice
Genotype Runx2-II+/+ Runx2-II+/ Runx2-II/
Max force (N)
6 weeks 25.1 T 5.4 18.7 T 3.3a
( P = 0.0028)
8.1 T 2.7a,b
( P = 0.0001)
24 weeks 37.8 T 6.4c 29.9 T 5.1a,c
( P = 0.0014)
–
( P = 0.0001) ( P < 0.0001)
Max deflection (mm)
6 weeks 0.85 T 0.11 0.86 T 0.05
( P = 0.8775)
0.81 T 0.09
( P = 0.3397)
24 weeks 0.56 T 0.11c 0.49 T 0.06c
( P = 0.0908)
–
( P < 0.0001) ( P < 0.0001)
Stiffness (N/mm)
6 weeks 48.1 T 12.5 34.3 T 6.2a
( P = 0.0024)
10.4 T 3.2a,b
( P < 0.0001)
24 weeks 93.0 T 16.9c 77.1 T 9.4a,c
( P = 0.0024)
–
( P < 0.0001) ( P < 0.0001)
Flexural rigidity (N.mm2)
6 weeks 125.2 T 32.6 89.2 T 16.1a
( P = 0.0024)
27.1 T 8.2a,b
( P < 0.0001)
24 weeks 242.2 T 44.0c 200.8 T 24.4a,c
( P = 0.0024)
–
( P < 0.0001) ( P < 0.0001)
Data are mean T SEM from 5 to 10 individual mice.
a Significant difference from wild-type Runx2-II+/+ mice.
b Significant difference from heterozygous Runx2-II+/ mice.
c Difference between 6 and 24 weeks at the indicated P value using
statistical analysis described in Materials and methods.
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Runx2-II+/ femurs exhibited significant increases in
bending strength (Fmax), Stiffness, and flexural rigidity
(EI), and a significant decrease in the maximum deflection
to failure (Table 4). Compared to age-matched Runx2-II+/+
mice, femurs from 6-week-old Runx2-II+/ mice exhibited
significantly reduced bending strength, stiffness, and
flexural rigidity. Femurs from 6-week-old Runx2-II/
mice exhibited further reductions in bending strength,
stiffness, and flexural rigidity compared to Runx2-II+/+ and
Runx2-II+/ mice (Table 4). At 24 weeks of age, femurs
from Runx2-II+/ mice still exhibited significantly lower
bending strength, stiffness, and flexural rigidity compared
to age-matched Runx2-II+/+ mice (Table 4).Discussion
To further understand the role of Runx-2 in skeletal
development, we characterized the structural, cellular, and
molecular abnormalities of adult mice selectively deficient
for Runx2-II, but with normal expression of the Runx2-I
isoform. Evidence for selective deficiency of Runx2-II in
mutant mice was confirmed by reduced Runx2-II mRNAlevels (Table 3) and prior electromobility shift assays
demonstrating a reduction in total Runx2 protein binding
to an OSE2 element (Xiao et al., 2004). In contrast to the
complete lack of skeletogenesis in the absence of both
Runx2-I and -II gene products, we found that selective
Runx2-II-deficient mice with normal Runx2-I expression
develop mineralized bone structures that are structurally
impaired. Loss of a single copy of Runx2-II isoform in
selective heterozygous Runx2-II deficiency is sufficient to
reduce BMD (Figs. 2 and 3) and impair mechanical strength
of bone (Table 4). Osteopenia in Runx2-II-deficient mice
was caused by a reduction in trabecular bone volume,
decreased number and thickness of trabecular bone, as well
as to a reduction of cortical thickness (Fig. 3 and Table 1).
Impaired osteoblastic function was the primary cause of
osteopenia in Runx2-II-deficient mice. Serum biochemical
markers and real-time PCR analysis of bone revealed that
Runx2-II-deficient mice have defects in osteoblast-mediated
bone formation (Table 3 and Fig. 4). In addition, BMSCs
derived from selective Runx2-II-deficient mice revealed a
defect of osteoblastic function in vitro as evidenced by
diminished alkaline phosphatase activity and mineralization
(Fig. 5). Age-dependent acquisition of BMD, however, was
preserved in Runx2-II-deficient mice, indicating that selec-
tive Runx2-II deficiency does not alter changes in bone
mass that are observed with growth.
We also observed evidence for reduced osteoclast
function in selective Runx2-deficient mice, including
decreased circulating TRAP levels and reduced expression
of osteoclastic markers in bone (Table 2). Since Runx2 is not
expressed in osteoclasts, these effects are likely mediated
through the osteoblastic factors RANK (receptor activator of
NF-nB) ligand, which promotes osteoclast formation, and
osteoprotegerin (OPG), which is an antagonist that com-
petes with RANK as a decoy receptor for RANK-L and thus
attenuates osteoclast differentiation (Kong and Penninger,
2000; Kong et al., 1999). Impairment of osteoclastic
differentiation in adult Runx2-II-deficient mice was asso-
ciated with a net deficiency of RANK-L activity (as a result
of no changes in OPG secretion and decreased RANK-L
synthesis leading to a gene-dose-dependent reduced RANK-
L/OPG ratio) (Katagiri and Takahashi, 2002). Our observa-
tions coincided with that of others, which report reduced
osteoclasts in non-selective Runx2-deficient mice (Yoda et
al., 2004) and an effect of Runx2 overexpression in
osteoblasts to induce osteoclast differentiation through in-
creased RANK-L (Enomoto et al., 2003; Geoffroy et al.,
2002). Collectively, these data suggest an important role of
Runx2-II in regulating the coupling of osteoblasts to
osteoclasts.
A gene-dose-dependent effect on bone formation has
been observed in the non-selective Runx2-deficient mice
lacking both functional Runx2-I and Runx2-II (Stein et al.,
2004; Tsuji et al., 2004). Similarly, the bone phenotype of
Runx2-II was also proportional to the gene dose, since
Runx2-II/ mice had a more severe osteopenia than
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selective Runx2-II mutant mice with the originally described
non-selective Runx2 mutant mice, however, revealed
differences between Runx2-I and -II function that cannot
be explained by gene-dose reduction. In this regard, se-
lective Runx2-II/ mice (Fig. 1D) are equivalent to the
non-selective Runx2+/ mice (Fig. 1A) with regards to gene-
dose reduction (namely, deleting half of the possible
transcripts), but in the first instance, this is achieved by
the absence of both copies of Runx2-II, and in the latter
instance, this is attained by deleting 1/2 of Runx2-I and
Runx2-II. The fact that selective Runx2-II/ mice have a
more severe skeletal phenotype than Runx2+/ (e.g., ap-
proximately 2-fold greater reduction in BMD) suggests the
possibility that Runx2-I and -II have distinct functions
imparted by their different N-termini (Fig. 2). Such
differential function of the N-termini might occur through
a functional domain that interacts with different co-factors
or enhanced DNA binding (Gu et al., 2000; Kundu et al.,
2002; Thirunavukkarasu et al., 1998; Xiao et al., 1999;
Yoshida et al., 2002).
The Runx2-II-deficient mouse skeletal phenotype also
may be the consequence of the site-specific functions of
Runx2 isoforms (i.e., intramembranous, perichondral/bone
collar/cortical, endochondral bone) (Chung et al., 2004;
Gerstenfeld et al., 2002). In this regard, in situ studies
indicate that Runx2-I is predominately expressed in pre-
hypertrophic chondrocytes and perichondrial/periosteal cell
giving rise to the bone collar and cortical bone (Choi et al.,
2002; Park et al., 2001), whereas Runx2-II expression
occurs in hypertrophic chondrocytes and osteoblasts (Inada
et al., 1999; Liu et al., 2001; Ueta et al., 2001). Consistent
with site- and cell-type-specific functions of Runx2-II
(Enomoto et al., 2000; Karsenty, 1999; Karsenty and
Wagner, 2002; Yamaguchi et al., 2000), heterozygous
Runx2-II-deficient mice have greater reductions in trabec-
ular than cortical bone volume (Figs. 3 and 4). Moreover,
the recovery of cortical bone with age in Runx2-II-deficient
mice (Table 1, Fig. 3) suggests that Runx2-I is sufficient for
increases in cortical bone mass that could arise as a
compensation for the lower trabecular bone mass.
In addition, we found that Runx2-II null mice had a
widened hypertrophic chondrocyte zone and impaired
remodeling of the metaphyseal region into trabecular bone
(Fig. 4). Since Runx2-II is strongly expressed in terminally
differentiated chondrocytes, this suggests a special role for
Runx2-II in the fate of hypertrophic chondrocytes and
subsequent endochondral bone formation as well as vascular
invasion into the cartilage, which was reported to be
impaired in the original Runx2/ mice (Enomoto et al.,
2000; Himeno et al., 2002). In contrast, chondrocyte
differentiation was inhibited before the prehypertrophic
stages in the original Runx2 null mice lacking both isoforms
(Inada et al., 1999; Takeda et al., 2001; Ueta et al., 2001).
A better understanding of the downstream effectors of
Runx2-II and/or cell-specific factors that underlie thedifferences in Runx2-II effects on bone remodeling in
trabecular and cortical bone is important to defining
molecular pathways that could be exploited to more ef-
fectively restore trabecular bone volume in osteoporotic
disorders. We identified decrements in the interstitial col-
lagenases MMP13 and MMP9 as well as vascular endothe-
lial growth factor (VEGF) in selective Runx2-II-deficient
mice, which raises the possibility that the growth plate
abnormalities are due to impaired matrix remodeling similar
to that observed in MMP9, MMP13, and VEGF null mice
(Himeno et al., 2002; Inada et al., 2004; Stickens et al.,
2004; Vu et al., 1998; Zelzer et al., 2001). Also, we
observed decreased expression of Type X collagen, a marker
of hypertrophic chondrocytes (Inada et al., 1999; Ueta et al.,
2001), but not Sox9 and Type II collagen in Runx2-II null
mice, consistent with the impairment of hypertrophic
chondrocytes maturation in the growth plate of selective
Runx2-II-deficient mice. We also found that osterix, a
previously reported downstream mediator of Runx2 (Naka-
shima et al., 2002), is also reduced in selective Runx2-II null
mice, along with a significant decrease osteoblastic markers
such as in alkaline phosphatase, osteocalcin, osteopontin,
MEPE, and DMP1, but not adipocyte markers lipoprotein
lipase (Lpl) and aP2. Finally, the reduction in Indian
hedgehog (Ihh) is consistent with the predominate function
of Runx2-II in regulating endochondral bone formation
(Yamaguchi et al., 2000), since mice lacking the Ihh gene
have no osteoblasts in endochondral bones, but have normal
intramembranous bone formation (Chung et al., 2001; Long
et al., 2004; St-Jacques et al., 1999). The loss of a single
copy of Runx2-II isoform is sufficient to cause osteopenia,
indicating the importance of Runx2 gene expression for
normal skeletal function.
In conclusion, our studies show that a normal comple-
ment of Runx2-II expression is required for optimal
osteoblast function in the adult bone. Our data suggest that
Runx2-II effects are dose-dependent and the loss of a single
copy of Runx2-II isoform is sufficient to cause osteopenia.
Overall, the structural, cellular, and biochemical changes in
Runx2-II-deficient mice resemble a low-turnover form of
osteopenia, where reduced bone formation exceeds the
reduction in bone resorption (Kawaguchi et al., 1999;
Rodan, 1991) and points to the important role that Runx2-
II gene products play in regulating osteoblast function post-
natally. In addition, Runx2 appears to have differential
effects on trabecular and cortical bone formation, possibly
reflecting a site-specific function of Runx2-II in osteoblasts
derived from sites of endochondral ossification. This site-
specific function might have clinical implications, since age-
related osteopenia is characterized by a greater loss of
cortical bone compared to trabecular bone (Kawaguchi et
al., 1999), whereas post-menopausal osteoporosis is char-
acterized by trabecular bone loss in excess of cortical bone
loss (Manolagas and Jilka, 1995). Additional differences
between Runx2-II and Runx2-I might reflect differences in
their respective N-termini. The selective deletion of Runx2-I
Z. Xiao et al. / Developmental Biology 283 (2005) 345–356 355will be required to more fully understand the differential
function of these two isoforms.Acknowledgments
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